National Pension Service grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,286,149 shares of the medical research company

Sequoia Financial Advisors LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 173,024 shares of the medical research company

NewEdge Advisors LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,040 shares of the medical research company

Amgen stock dropped about 10 percent on September 8, 2026 as investors reacted to cardiovascular tri

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) reported results from a late-stage clinical trial evaluating a combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi as a maintenance treatment for extensive-stage small-cell lung cancer.

Baird Financial Group Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 339,825 shares of the medical research company

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]